Economy
Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
Publication and source
PublicationSanalda Haber
SourceMarketWatch
Published
CategoryEconomy
Summary from the source publisher’s news feed.